Skip to Content

Generic Uceris Availability

Uceris is a brand name of budesonide, approved by the FDA in the following formulation(s):

UCERIS (budesonide - tablet, extended release;oral)

  • Manufacturer: VALEANT PHARMS INTL
    Approval date: January 14, 2013
    Strength(s): 9MG [RLD]

Has a generic version of Uceris been approved?

No. There is currently no therapeutically equivalent version of Uceris available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Uceris. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Controlled release and taste masking oral pharmaceutical composition
    Patent 7,410,651
    Issued: August 12, 2008
    Inventor(s): Villa; Roberto & Pedrani; Massimo & Ajani; Mauro & Fossati; Lorenzo
    Assignee(s): Cosmo Technologies Limited
    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Patent expiration dates:
    • June 9, 2020
      ✓ 
      Patent use: INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical compositions
    Patent 7,431,943
    Issued: October 7, 2008
    Inventor(s): Villa; Roberto & Pedrani; Massimo & Fossati; Mauro Ajani & Fossati; Lorenzo
    Assignee(s): Cosmo Technologies Limited
    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Patent expiration dates:
    • June 9, 2020
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical composition
    Patent 8,293,273
    Issued: October 23, 2012
    Inventor(s): Villa; Roberto & Pedrani; Massimo & Ajani; Mauro & Fossati; Lorenzo
    Assignee(s): Cosmo Technologies Limited
    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Patent expiration dates:
    • June 9, 2020
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical composition
    Patent 8,784,888
    Issued: July 22, 2014
    Assignee(s): Cosmo Technologies Limited
    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Patent expiration dates:
    • June 9, 2020
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical composition
    Patent 8,895,064
    Issued: November 25, 2014
    Assignee(s): Cosmo Technologies Limited
    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Patent expiration dates:
    • September 7, 2031
      ✓ 
      Drug product
  • Controlled release and taste making oral pharmaceutical composition
    Patent 9,132,093
    Issued: September 15, 2015
    Assignee(s): COSMO TECHNOLOGIES LIMITED
    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Patent expiration dates:
    • September 7, 2031
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical composition
    Patent 9,192,581
    Issued: November 24, 2015
    Assignee(s): COSMO TECHNOLOGIES LIMITED
    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Patent expiration dates:
    • September 7, 2031
      ✓ 
      Patent use: INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical compositions
    Patent 9,320,716
    Issued: April 26, 2016
    Assignee(s): COSMO TECHNOLOGIES LIMITED
    The invention relates to an oral pharmaceutical composition comprising an active agent, a macroscopically homogeneous structure and a gastro-resistant coating. The macroscopically homogeneous structure comprises at least one hydrophilic compound and at least one lipophilic compound and/or at least one amphiphilic compound. The macroscopically homogeneous structure controls the release of the active ingredient, and the gastro-resistant film prevents release of the active agent in the stomach.
    Patent expiration dates:
    • June 9, 2020
      ✓ 
      Patent use: INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical composition
    Patent RE43799
    Issued: November 13, 2012
    Inventor(s): Villa; Roberto & Pedrani; Massimo & Ajani; Mauro & Fossati; Lorenzo
    Assignee(s): Cosmo Technologies Limited
    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Patent expiration dates:
    • June 9, 2020
      ✓ 
      Patent use: INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • January 14, 2016 - NEW DOSAGE FORM

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide